High Hepatic and Extrahepatic Mortality and Low Treatment Uptake in HCV-coinfected Persons in the Swiss HIV Cohort Study between 2001 and 2013 by Kovari, Helen et al.
Accepted Manuscript
High Hepatic and Extrahepatic Mortality and Low Treatment Uptake in HCV-
coinfected Persons in the Swiss HIV Cohort Study between 2001 and 2013
Helen Kovari, Bruno Ledergerber, Matthias Cavassini, Juan Ambrosioni,
Andrea Bregenzer, Marcel Stöckle, Enos Bernasconi, Roger Kouyos, Rainer
Weber, Andri Rauch, the Swiss HIV Cohort Study
PII: S0168-8278(15)00302-5
DOI: http://dx.doi.org/10.1016/j.jhep.2015.04.019
Reference: JHEPAT 5657
To appear in: Journal of Hepatology
Received Date: 11 December 2014
Revised Date: 17 March 2015
Accepted Date: 21 April 2015
Please cite this article as: Kovari, H., Ledergerber, B., Cavassini, M., Ambrosioni, J., Bregenzer, A., Stöckle, M.,
Bernasconi, E., Kouyos, R., Weber, R., Rauch, A., the Swiss HIV Cohort Study, High Hepatic and Extrahepatic
Mortality and Low Treatment Uptake in HCV-coinfected Persons in the Swiss HIV Cohort Study between 2001
and 2013, Journal of Hepatology (2015), doi: http://dx.doi.org/10.1016/j.jhep.2015.04.019
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers
we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and
review of the resulting proof before it is published in its final form. Please note that during the production process
errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
s
o
u
r
c
e
:
 
ht
tp
s:
//
do
i.
or
g/
10
.7
89
2/
bo
ri
s.
69
04
2 
| 
do
wn
lo
ad
ed
: 
13
.3
.2
01
7
  
17.03.2015 1 of 26 
High Hepatic and Extrahepatic Mortality and Low Treatment Uptake in HCV-
coinfected Persons in the Swiss HIV Cohort Study between 2001 and 2013  
 
Helen Kovari1, Bruno Ledergerber1, Matthias Cavassini2, Juan Ambrosioni 3, Andrea 
Bregenzer4, Marcel Stöckle5, Enos Bernasconi6, Roger Kouyos1,7, Rainer Weber1*, 
Andri Rauch8*, and the Swiss HIV Cohort Study 
 
1 Division of Infectious Diseases and Hospital Epidemiology, University Hospital, 
Zurich, University of Zurich, Switzerland 
2 Division of Infectious Diseases, University Hospital, Lausanne, Switzerland 
3 Division of Infectious Diseases, University Hospital, Geneva, Switzerland 
4 Division of Infectious Diseases, Cantonal Hospital, St. Gall, Switzerland 
5 Division of Infectious Diseases and Hospital Epidemiology, University Hospital, 
Basle, Switzerland 
6 Ospedale Regionale, Lugano, Switzerland 
7 Institute of Medical Virology, University of Zurich, Switzerland 
8 University Clinic of Infectious Diseases, University Hospital Berne and University of 
Berne, Berne, Switzerland 
 
*contributed equally to this study. 
 
Corresponding author:  
Helen Kovari, M.D. 
Division of Infectious Diseases and Hospital Epidemiology 
University Hospital Zurich, University of Zurich 
Rämistrasse 100, 
  
17.03.2015 2 of 26 
CH-8091 Zurich, Switzerland 
Tel +41 44 255 91 95 or +41 44 255 11 11 
Fax +41 44 255 32 91 
Email: helen.kovari@usz.ch 
 
Word count: 4664  
Number of figures and tables: 5  
Supplementary table: 1 
 
List of abbreviations:  
ALT, alanine aminotransferase 
AST, aspartate aminotransferase 
ART, antiretroviral therapy 
DAA, direct-acting antiviral drug 
HBV, hepatitis B virus 
HCV, hepatitis C virus 
IDU, intravenous drug user 
IFN, interferon 
MSM, men who have sex with men 
pegIFN, pegylated interferon 
PY, person years 
RBV, ribavirin 
SHCS, Swiss HIV Cohort Study 
SVR, sustained virological response 
 
Key words: HCV, HIV, mortality, treatment, epidemiology 
  
17.03.2015 3 of 26 
Conflict of interest:   
All authors: no reported conflicts. 
 
Financial support:  
This study was funded within the framework of the Swiss HIV Cohort Study, 
supported by the Swiss National Science Foundation (grant # 134277), and with an 
unrestricted grant by Gilead Sciences. 
 
Author’s contribution:  
HK, BL, RW and AR concepted and designed the study. HK, MC, JA, AB, MS, EB, 
RW and AR were responsible for the data acquisition. BL analyzed the data. All 
authors interpreted the data. HK and AR prepared the paper. All authors read and 
approved the final manuscript. 
 
 
 
  
17.03.2015 4 of 26 
ABSTRACT  
Background & Aims: The landscape of HCV treatments is changing dramatically. At 
the beginning of this new era, we highlight the challenges for HCV-therapy by 
assessing the long-term epidemiological trends in treatment uptake, efficacy and 
mortality among HIV/HCV-coinfected people since the availability of HCV therapy. 
Methods: We included all SHCS participants with detectable HCV RNA between 
2001 and 2013. To identify predictors for treatment uptake uni- and multivariable 
Poisson regression models were applied. We further used survival analyses with 
Kaplan-Meier curves and Cox regression with drop-out as competing risk. 
Results: Of 12,401 participants 2107 (17%) were HCV RNA positive. Of those, 636 
(30%) started treatment with an incidence of 5.8/100 person years (PY) (95% CI 5.3-
6.2). Sustained virological response (SVR) with pegylated interferon/ribavirin was 
achieved in 50% of treated patients, representing 15% of all participants with 
replicating HCV infection. 344 of 2107 (16%) HCV RNA positive persons died, 59% 
from extrahepatic causes. Mortality/100 PY was 2.9 (95% CI 2.6-3.2) in untreated 
patients, 1.3 (1.0-1.8) in those treated with failure, and 0.6 (0.4-1.0) in patients with 
SVR. In 2013, 869/2107 (41%) participants remained HCV RNA positive.  
Conclusions: Over the last 13 years HCV treatment uptake was low and by the end 
of 2013, a large number of persons remain to be treated. Mortality was high, 
particularly in untreated patients, and mainly due to non-liver related causes.  
Accordingly, in HIV/HCV-coinfected patients, integrative care including the diagnosis 
and therapy of somatic and psychiatric disorders is important to achieve mortality 
rates similar to HIV-monoinfected patients.  
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INTRODUCTION 
The treatment of hepatitis C virus (HCV) infection in HIV-infected patients has 
changed dramatically in the last decades. Before 1990, HCV infection was incurable. 
Subsequently, sustained viral response (SVR) was only about 10% with interferon 
monotherapy [1]. After 2000, and until recently, the pegylated interferon and ribavirin 
(pegIFN/RBV) combination therapy improved outcome substantially, but still resulted 
in modest SVR of 14-29% for genotype 1, and 44-73% for genotypes 2 or 3 [2-4]. 
Although successful treatment of chronic HCV-infection decreased liver-specific and 
all-cause mortality [5, 6], rates of treatment uptake in the HIV-coinfected population 
were low [7]. Barriers to start treatment included comorbid medical and psychiatric 
conditions, active substance abuse with the inability to adhere to complex HCV 
treatment regimens, expected adverse effects of or contraindications for HCV 
combination therapy, and uncontrolled HIV disease (reviewed in [7]).  
     With the availability of direct-acting antivirals (DAAs), the landscape of HCV 
treatment is changing rapidly. New treatment options with high cure rates for 
HIV/HCV-coinfected patients are now available or will be approved shortly. At the 
beginning of this new era, documentation of the long-term epidemiological trends, 
treatment uptake, outcome and mortality of HCV-infections is important to adequately 
assess the impact of new therapies. Moreover, physicians and public health 
authorities need information on the proportion of patients with replicating HCV- 
infection, on HCV genotype distribution and on liver-related complications in 
representative populations. This information is key to define the most urgent 
treatment priorities, and to optimally invest the available resources in order to reduce 
HCV-related mortality in HIV-infected patients.  
     The Swiss HIV Cohort Study (SHCS) offers an ideal platform to study the natural 
course of HCV-infection and long-term influence of HCV treatments in a nation-wide 
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representative population of HIV-infected patients. We aimed to i), assess the 
changes in epidemiology, clinical course and therapy of HCV-infections between 
2001 and 2013, and ii), to characterize the population who remains eligible for the 
new HCV treatment options by the end of 2013.  
 
PATIENTS AND METHODS 
Swiss HIV Cohort Study 
The SHCS is an ongoing, prospective cohort study that continuously enrolls and 
observes HIV-infected adults at 5 university outpatient clinics, 2 large district 
hospitals, affiliated regional hospitals, and private practices, since 1988. This 
nationwide cohort covers 69% of all patients living with AIDS, and 75% of persons 
receiving antiretroviral therapy (ART) in Switzerland [8, 9]. Demographic, clinical and 
laboratory data are collected at registration and every 6 months thereafter using a 
standard protocol. The protocol was approved by local ethical review boards, and 
written informed consent was obtained from all participants.  
     The indication for HCV therapy and treatment monitoring is provided by HIV- and 
HCV-trained infectious diseases specialists in the same clinical setting as HIV 
therapy. 
 
Laboratory measurements and data collection  
All SHCS participants are routinely screened for HCV antibodies at study entry. Since 
1998, serology was repeated every second year of follow-up in participants with 
previously negative results. Starting routinely in 2002, quantitative HCV RNA 
measurements and HCV genotype determination were undertaken in HCV-
seropositive persons.  
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     In addition to the information retrieved from the SHCS database, detailed 
information on HCV-infection, on treatment history and outcomes was obtained by 
retrospective chart review using a structured questionnaire. Deaths were classified 
as liver-related (including cirrhosis and liver cancer), HIV/AIDS, cardiovascular, non-
liver cancer, sepsis due to any cause (including bacterial and candida septicemia, 
endocarditis, pneumonia, bacterial meningitis), drug-related, and other causes. All 
events neither related to HCV infection nor to other liver diseases were classified as 
extrahepatic events. Events involving other organs than the liver, but clearly 
associated with liver cirrhosis, including variceal hemorrhage and hepatorenal 
syndrome, were classified as liver-related.  
 
Patients’ selection 
All SHCS participants with at least one study visit between 1 January 2001, the date 
when pegIFN became available for HIV/HCV-coinfected patients in Switzerland, and 
31 December 2013 were included in these analyses. Patients treated with standard 
IFN (with or without RBV) were excluded (n=22).  
 
Definitions  
HCV treatment outcomes were defined as SVR, relapse, or nonresponse, according 
to standard definitions [10]. SVR was defined as at least one negative HCV RNA test 
≥12 weeks after the end of treatment [11]. Patients without an HCV RNA test after 
the end of treatment were classified as nonresponders if their HCV RNA remained 
positive during treatment (n=8), and were excluded if their HCV RNA was 
undetectable at the end of treatment or at the last on-treatment test (n=6), or if they 
had no available on-treatment HCV RNA value (n=22). A treatment course was 
considered terminated if pegIFN was discontinued for ≥30 days. 
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     Liver fibrosis stage was derived from liver biopsy using the METAVIR scoring 
system [12], or alternatively from transient elastography (Fibroscan®, Echosens 
S.A.S.U., Paris, France), with cut-off values of ≥9.5 kPa for Metavir ≥F3 and >12.5 
kPa for Metavir F4 [13]. Liver biopsy was not mandatory prior to the initiation of 
HCV treatment. Patients were selected for liver biopsy by physicians’ choice and 
patient willingness. Use of transient elastography started in 2005 in Switzerland. 
The two non-invasive biomarkers of liver fibrosis FIB-4 and APRI were calculated 
as follows: FIB-4: (age x AST)/[platelet count (109cells/L) x sqr(ALT)], and APRI: 
[(AST/ULN)/platelet count] x 100. A FIB-4 value >3.25, and an APRI score >1.5 is 
indicative for fibrosis stage F3/4 [14, 15]. Undetectable HIV RNA was defined by 
values <50 copies/mL. Hepatitis B virus (HBV) infection was defined by a positive 
hepatitis B surface antigen or detectable viral load. Data on alcohol use was 
collected by a questionnaire on self-reported alcohol consumption. Severe alcohol 
abuse was defined according to the WHO definition (female >40g/d, male 
>60g/d). Psychiatric disorder was defined by treatment with psychotropic drugs, 
and after 2008 by a diagnosis of depression.  
 
Statistical Analysis 
Treatment uptake analyses 
For the analyses of treatment uptake, all HCV-seropositive SHCS participants with 
positive HCV RNA and at least 2 visits were included. They were followed up to their 
last visit, death, or the date of starting HCV therapy. We used univariable and 
multivariable Poisson regression models to identify predictors for treatment uptake. 
Baseline was defined as 1 January 2001 or the date of the first detectable HCV RNA 
whichever occurred later. Fixed covariables included age, sex, HIV transmission risk 
group, HCV genotype, HCV RNA level, CD4 cell count, ART with or without HIV RNA 
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<50 copies/mL, psychiatric disorder, type of health care provider and calendar period 
(2001-2004, 2005-2007, 2008-2010, 2011-2013). Characteristics of treated patients 
at treatment start and untreated patients at last follow-up were compared using 
Fisher’s exact tests for categorical and Wilcoxon rank-sum tests for continuous 
variables. 
Treatment efficacy analyses 
Treatment outcomes were analyzed separately for genotype 1 and 4, respectively 2 
and 3, because of the different SVR rates by genotype. Early therapies in acute HCV 
infections and DAA treatment regimens (in Switzerland available after November 
2011, n=57) were not considered for the analyses of treatment outcome. In patients 
with multiple treatment courses, only the first course was evaluated for treatment 
uptake and outcome. Time trends were analyzed using non-parametric tests for 
trend. 
Survival analyses 
Survival analyses of participants with at least two follow-up visits were performed 
using Kaplan-Meier curves and Cox regression with drop-out as competing risk. 
Baseline was defined as the date of the first visit after 1 January 2001.  
We used Stata/SE 13.1 (StataCorp, College Station, Texas, USA) for all analyses. 
 
RESULTS  
Study population  
Of 12’401 SHCS participants followed between 1 January 2001 and 31 December 
2013, 2956 (23.8%) were HCV antibody positive, and 2107 (17.0%) were HCV RNA 
positive (Figure 1). In 415 patients HCV RNA was not available (Figure 1). Of those, 
42.0% died and 39.5% left the cohort in the first years after the approval of 
pegIFN/RBV therapy in Switzerland, in a time period where HCV RNA was not 
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collected systematically. HCV RNA tested vs HCV RNA untested patients did not 
differ regarding sex, age, and HIV transmission mode (all P>0.1). HCV RNA positive 
patients had in 43% genotype 1, in 3% genotype 2, in 25% genotype 3, in 16% 
genotype 4, and in 0.1% genotype 6 infections. The proportion of men was 69% and 
median age at registration was 33 years. The distribution of HIV transmission group 
was 69% intravenous drug users (IDU), 16% heterosexuals and 12% men who have 
sex with men (MSM). The treatment providers were university centers (62%), 
affiliated hospitals (12%), and private HIV practitioners (27%) (Table 1). Of 2519 
HCV seropositive patients with available HCV RNA values 491 (19.5%) cleared HCV 
spontaneously. 
 
HCV treatment uptake 
The 2107 HCV RNA positive participants contributed to 10,764 person years (PY). 
1471 (70%) participants never received HCV therapy, whereas 636 (30%) started 
treatment between 2001 and 2013, resulting in an overall incidence of 5.8/100 PY 
(95% CI 53-6.2); 6.6 (5.7-7.6) before 2004, 5.2 (4.4-6.1) between 2005-2007, 5.3 
(4.5-6.2) between 2008-2010, and 6.1 (5.1-7.2) between 2011-2013. The incidence 
of treatment start was 5.3 (4.7-6.0) in genotype 1, 5.0 (3.0-8.1) in genotype 2, 9.7 
(8.5-11.0) in genotype 3, and 3.4 (2.7-4.3) in genotype 4 infections.  
     Characteristics of HCV treated and untreated participants at date of treatment 
start or date of last follow-up visit are displayed in Table 1. Untreated patients missed 
more appointments during the follow-up period (FUP). Mean number of missed 
appointments/year during FUP for untreated vs treated patients were 0.05 and 0.02, 
respectively (p <0.001). In the multivariable model, predictors for treatment uptake 
were genotype 3, younger age, MSM, CD4 cell count >200 cells/µL, absence of 
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psychiatric disorders, and being under the care of an HIV practitioner. Treatment 
uptake did not change significantly between time periods (Table 2). 
     Of 636 treated patients, 11% were treated twice, and 2% had ≥3 treatment cycles. 
144 (6.8%) of 2107 HCV RNA positive infections were incident infections. Of these, 
39 (27%) were treated early within 6 months after first HCV diagnosis. 
 
Treatment outcome  
Between 2001 and 2013, SVR was achieved in 321 of 636 (50.5%) treated 
participants. In chronic therapy-naïve genotype 1 and 4 infections, treated with 
pegIFN/RBV, overall SVR was 35.2% (95/270); 32.6% before 2005, 23.4% between 
2005-2007, 44.3% between 2008-2010, and 54.6% between 2011-2013 (test for 
trend, P=0.03). In genotype 2 and 3 infections, overall SVR was 68.4% (167/244); 
and 63.9%, 72.5%, 72.3%, and 67.7% in the different time periods, respectively 
(P=0.37). Liver transplantation because of HCV-associated end-stage liver disease 
was performed in 11 coinfected participants.  
 
Mortality  
Mortality (per 100 PY) was 2.9 (95% CI 2.6-3.2) in HCV-coinfected participants who 
were not HCV treated, 1.3 (1.0-1.8) in treated patients with treatment failure, 0.6 (0.4-
1.0) in treated patients with SVR, and 0.9 (0.8-1.0) in participants without HCV-
coinfection. This pattern was confirmed in Cox regression with drop-out as competing 
risk, resulting in subhazard ratios of 3.0 (95% CI 2.6-3.4, P<0.001) for untreated, 1.6 
(1.2-2.2, P=0.001) for treated patients without SVR, and 0.8 (0.5-1.3, P=0.3) for 
patients with SVR, compared with participants not coinfected with HCV. Subhazard 
ratio for treated patients without SVR vs. SVR was 2.1 (1.2-3.6, P=0.009), and for 
untreated vs. treated participants with failure 1.9 (1.4-2.5, P<0.001) (Figure 2). 
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Baseline characteristics of HCV negative, HCV positive treated and untreated 
patients are shown in the supplementary Table S1. 
     Among the HCV untreated participants, a total of 295/1471 (20.1%) died. Causes 
of death were liver-related (38.0%), HIV/AIDS (17.6%), sepsis (15.0%), and 
cardiovascular diseases (12.4%) in 193 participants with known causes of death. In 
the treated group 49/636 (7.7%) patients died; causes were liver-related (59.4%), 
sepsis (19.4%), HIV-AIDS (8.3%), and cardiovascular diseases (5.6%) in 32 patients 
with known causes of death.  
 
Temporal changes in the characteristics of the HCV-positive population  
Figure 3A shows temporal changes in outcomes of all SHCS participants with active 
HCV infection between 2001 and 2013. Figure 3B depicts the genotype distribution 
among SHCS participants with a replicating HCV infection over time. The proportion 
of genotype 1 treatment naïve participants decreased from 45.3% in 2001 to 37.5% 
in 2013, and HCV replicating treatment experienced patients increased from 2.1% to 
15.4%. Genotype 3 treatment naïve individuals decreased from 29.5% to 14.7%, and 
HCV-replicating treatment experienced increased from 2.1% to 6.4%. The proportion 
of genotype 4 treatment naïve infections remained stable with 17.2% in 2001 and 
18.0% in 2013. Figure 3C shows the distribution of HIV transmission risk groups 
among SHCS participants with a replicating HCV infection. The proportion of IDUs 
among participants with HCV RNA positive infections decreased from 73.2% in 2001 
to 63.9% in 2013, heterosexuals remained almost stable with 15.1% in 2001 and 
18.4% in 2013, whereas the proportion of MSM increased from 6.1% to 14.2%.  
 
Characteristics of patients with replicating HCV infection in 2013 
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By the end of 2013, 869/2107 (41.2%) HCV RNA positive participants seen between 
2000 and 2013 had replicating HCV infection: 699 were treatment naïve, 60 
relapsers, and 110 non-responders. Genotype distribution was: 1, 384 (44.2%); 2, 24 
(2.8%); 3, 161 (18.5%); 4, 174 (20.0%); other/unknown, 126 (14.5%). FIB-4 was 
>3.25 in 123 (14.2%) and APRI >1.5 in 173 (19.9%) of all patients. In 408 
participants with available biopsy or transient elastography 81 (19.9%) had F2 
fibrosis, 40 (9.8%) advanced liver fibrosis F3 in, and 65 (15.9%) cirrhosis F4. Most of 
the participants, 561 (64.6%), were IDU, 162 (18.6%) heterosexuals, and 118 
(13.6%) MSM (Figure 3).  
 
DISCUSSION 
This is one of the largest nationwide community-based HIV cohort studies describing 
the long-term changes in epidemiology, treatment uptake, efficacy, and mortality of 
HCV-coinfection since the availability of HCV treatment. We found that of 12,401 
cohort participants 24% were HCV-seropositive and 17% were HCV RNA positive. Of 
those with replicating HCV-infection, 30% were treated and 15% were cured during a 
follow-up period of thirteen years. During the observation period 16% of participants 
with active HCV-infection died, 59% due to extrahepatic complications. 41% 
remained with replicating HCV-infection. Taken together, only a minority of HCV-
infected participants benefited from HCV therapy in the last two decades while a 
large part of patients still awaits treatment. By the end of 2013, 14 to 20% of 
coinfected individuals had advanced fibrosis or cirrhosis and thus an urgent 
indication for therapy; 20% of participants are treatment experienced and may thus 
be more difficult to cure even with DAA therapies. However, most patients did not die 
from liver-related complications, irrespective of treatment history. This indicates the 
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importance of integrative care of HIV/HCV-coinfected individuals including the 
diagnosis and treatment of somatic and psychiatric disorders. 
     The incidence of treatment uptake of 5.8 per 100 PY and a treatment rate of 30% 
in the SHCS is similar to recent data from other European cohorts. In the EuroSIDA 
study treatment incidence ranged between 2.22 and 5.93/100 PY between 2001 and 
2010 [16], and in a German and Swedish HIV/HCV cohort treatment rates were 40% 
and 25%, respectively [17, 18]. In a large US cohort of veterans only 12% of 
monoinfected patients received therapy between 2000 and 2005 [19]; in coinfected 
populations treatment uptake was even lower [20, 21]. Predictors for treatment 
uptake, including genotype 3, MSM, younger age, no psychiatric disorders and 
controlled HIV-infection, indicate that therapy was started in the easier-to-treat 
patients. This is consistent with data from other studies [7, 16, 18]. Treatment uptake 
over time did not change significantly in our cohort.  
     The overall SVR rates of 35.2% in genotypes 1 and 4, respectively 68.4% in 
genotypes 2 and 3 are comparable to cure rates achieved in randomized controlled 
trials in coinfected patients [2-4]. In genotypes 1 and 4, SVR significantly increased 
over time. The use of weight-based ribavirin and extended treatment duration after 
2008 together with increased provider experience might have resulted in higher cure 
rates in the more difficult-to-treat genotypes. The decision to treat after the discovery 
of IL28B haplotype 2009 was not influenced relevantly by this parameter. In the 
SHCS, IL28B was determined mainly in the frame of retrospective studies [22] and 
was only very rarely used in clinical decision algorithms.  
     Mortality was 16% in our HIV/HCV-coinfected cohort. This is comparable to the 
mortality rate of 14% in a US hepatitis C cohort with 3% coinfected patients [23]. SVR 
was strongly associated with lower mortality rates in comparison to treated patients 
with failure. This is in accordance with recent studies finding a reduction of mortality 
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and liver-related events in successfully treated patients [5, 24, 25]. In HCV-untreated 
patients risk of death was significantly higher compared to HCV-treated and HIV-
monoinfected patients, and also significantly higher compared to treated patients with 
failure (Figure 2). Only about 40% of deaths were liver-related in this group, in line 
with data from other HIV/HCV cohorts with high extrahepatic mortality rates [23, 26]. 
The reason for high mortality among untreated patients may be associated with the 
fact that they mainly belonged to the IDU transmission group, more likely currently 
injected drugs, reported severe alcohol use, and had less well controlled HIV-
infection (Table 1). This indicates also that this group may be generally more 
challenging to treat. These findings underscore the important contribution of social, 
behavioral and clinical factors associated with increased mortality in HIV/HCV-
coinfected patients [23]. Therefore, although curing HCV is an important achievement 
in the care of these patients, addressing somatic and psychiatric comorbidities is key 
to reducing mortality in this population.  
     The proportion of the heterosexual HIV transmission group among patients with 
active HCV infection remained approximately stable in the last 13 years, whereas the 
percentage of IDUs decreased and that of MSM increased. The decrease in the 
proportion of IDUs can be attributed to successful preventive interventions including 
methadone substitution and needle exchange programs reducing HCV transmission 
in this population. Although MSM were more likely to be treated compared to patients 
from other transmission groups their proportion clearly increased reflecting the rise of 
incident HCV-infections in MSM in the SHCS which has been previously shown [27]. 
Despite the increased probability of HCV genotype 3 infected patients to start 
therapy, the distribution of genotypes did not change noticeably over time. 
     Major strengths of this study include the large number of patient-years with 
prospectively collected laboratory and clinical data, regular HCV-screening, and a 
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long follow-up time. Furthermore, the study provides information to physicians and 
public health authorities on the most urgent needs when planning future HCV 
interventions in a nation-wide representative community based cohort of HIV-infected 
patients. Our study has several limitations. We did not capture information on 
contraindications and adverse events of HCV treatment as a reason for deferring 
therapy or early treatment stop. Another limitation is the lack of vital status 
information of patients who left the cohort because of very restrictive legislation about 
linkage with death registries in Switzerland. To account for this limitation we have 
applied analyses with drop-out as competing risk.  
     In summary, the long-term assessment of HCV treatment uptake and outcome in 
this large HIV/HCV-coinfected population revealed a low treatment uptake, which did 
not increase over time. Treatment efficacy was comparable to results of randomized 
trials. However, due to the high mortality rate, the number of patients who died was 
similar to the number of patients who were cured from HCV infection during follow-
up. Most deaths were not liver-related and mortality rate was significantly higher in 
those who did not start treatment compared to those with treatment failure, indicating 
that diseases other than HCV are important risk factors for mortality in these patients. 
By the end of 2013, a large number of HCV-coinfected SHCS participants remain to 
be treated. Oral DAA therapies with better tolerability, shorter treatment duration and 
significantly higher efficacy will allow treating many of the difficult–to-treat patients. 
Interferon-free DAA therapies could overcome most of the treatment barriers 
identified in our study (Table 2), including non-3 genotypes, higher age, IDU, low 
CD4 cell counts and psychiatric disorders. Within the next few years, the extent of 
the impact of the new treatments on the burden of liver disease in the coinfected 
population remains to be defined. In this context, our findings underscore the 
importance of efforts for optimizing care of comorbidities in HIV/HCV-coinfected 
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patients, given that curing HCV alone is not sufficient to achieve mortality rates 
similar to HIV-monoinfected patients. 
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Table 1: Characteristics of HIV/HCV-coinfected cohort participants at date of last follow-up visit or HCV treatment uptake, 2001-2013. 
 
  
 Total Untreated Treated P-value 
  
No. of patients  2107 1471 636  
  
Male gender (%) 1447 (68.7) 971 (66.0) 476 (74.8) <0.001 
  
Median age at registration   years (IQR) 33 (28-38) 33 (28-38) 32 (28-38) 0.4 
  
HIV transmission group (%)   MSM  249 (11.8) 138 (9.4) 111 (17.5) <0.001 
     IDU  1454 (69.0) 1056 (71.8) 398 (62.6)  
     Heterosexual 343 (16.3) 244 (16.6) 99 (15.6)  
     Other 61 (2.9) 33 (2.2) 28 (4.4)  
  
HCV genotype (%)   1 910 (43.2) 637 (43.3) 273 (42.9) <0.001 
     2 57 (2.7) 41 (2.8) 16 (2.5)  
     3 534 (25.3) 288 (19.6) 246 (38.7)  
     4 334 (15.9) 264 (18.0) 70 (11.0)  
     Other/unknown 272 (12.9) 241 (16.4) 31 (4.9)  
  
HCV RNA     ≥800’000 IU/ml 1019 (48.4) 678 (46.1) 341 (53.6) <0.001 
     <800’000 IU/ml 1017 (48.3) 732 (49.8) 285 (44.8)  
     Unknown 71 (3.4) 61 (4.2) 10 (1.6)  
  
ALT, U/L    median (IQR) 45 (27-80) 45 (27-74) 45 (25-102) 0.6 
AST U/L    median (IQR) 43 (30-72) 43 (30-69) 43 (27-80) 0.9 
Platelet count (k/µL)   median (IQR) 197 (154-253) 199 (157-256) 191 (140-237) 0.08 
  
FIB-4     available, n (%) 623 (29.6) 458 (31.1) 165 (25.9)  
     median (IQR) 1.26 (0.8-2.1) 1.23 (0.9-2.0) 1.33 (0.8-2.2) 0.6 
     >3.25, n (%) 72 (11.6) 48 (10.5) 24 (14.6) 0.3 
  
APRI     available, n (%) 623 (29.6) 458 (31.1) 165 (25.9)  
     median (IQR)  0.47 (0.3-0.9) 0.46 (0.3-0.8) 0.54 (0.3-0.9) 0.2 
     >1.5, n (%) 126 (20.2) 86 (18.8) 40 (24.4) 0.02 
   
Fibrosis score (Fibroscan, biopsy) available, n (%) 764 (36.3) 389 (26.4) 375 (59.0)  
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     Metavir ≥F3 253 (33.1) 74 (19.0) 179 (47.7) <0.001 
  
CD4 cells/µl     median (IQR) 449 (287-651) 447 (273-659) 451 (312-616) 0.7 
     ≤200 cells/µl, n (%) 298 (14.1) 245 (16.7) 53 (8.3) <0.001 
  
On ART     all 1574 (74.7) 1038 (70.6) 536 (84.3) <0.001 
     HIV RNA undetectable  1370 (87.0) 887 (85.5) 483 (90.1) 0.009 
  
Hepatitis B infection 112 (5.3) 76 (5.2) 36 (5.7) 0.6 
  
Psychiatric disorder 430 (20.4) 330 (22.4) 100 (15.7) <0.001 
  
Opiate maintenance program 864 (41.0) 703 (47.8) 161 (25.3) <0.001 
Active intravenous drug use 306 (14.5) 255 (17.3) 51 (8.0) <0.001 
Severe alcohol abuse 281 (13.3) 208 (14.1) 73 (11.5) <0.001 
  
Type of health care provider  University center 1299 (61.7) 932 (63.3) 367 (57.7) 0.003 
  
     Affiliated hospital 243 (11.5) 176 (12.0) 67 (10.5)  
     Private physician 565 (26.8) 363 (24.7) 202 (31.8)  
  
Treating time period   2001-2004 
     2005-2007 
     2008-2010 
     2011-2013 
 
197 (31.0)
164 (25.8)
150 (23.6)
125 (19.7)
 
 
*p-values were calculated by Fisher’s exact tests for categorical and Wilcoxon rank-sum tests for continuous variables.  
Abbreviations:  ALT, alanine aminotransferase; ART, antiretroviral therapy; AST, aspartate aminotransferase; HBV, hepatitis B virus; HCV, hepatitis C virus;  IDU, 
intravenous drug user; IQR, interquartile range; MSM, men who have sex with men. 
 
 
 
 
 
Table 2: Uni- and multivariable Poisson regression models for predictors associated with hepatitis C virus (HCV) treatment uptake in the SHCS, 2001-2013. 
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 Univariable Analysis Multivariable Analysis 
 
 IRR (95% C.I.) P-value IRR (95% C.I.) P-value 
Age group, years   16-29 Ref.  Ref.  
     30-39 0.61 (0.41-0.91) 0.02 0.63 (0.42-0.95) 0.03 
     40-49  0.63 (0.43-0.92) 0.02 0.63 (0.42-0.94) 0.03 
     >49 0.41 (0.27-0.63) <0.001 0.35 (0.22-0.54) <0.001 
     
HIV transmission group (%)   MSM  Ref.  Ref.  
     Heterosexual, female 0.29 (0.20-0.42) <0.001 0.25 (0.17-0.36) <0.001 
     Heterosexual, male 0.44 (0.32-0.61) <0.001 0.37 (0.27-0.52) <0.001 
     IDU, female 0.28 (0.22-0.37) <0.001 0.21 (0.16-0.28) <0.001 
     IDU, male 0.38 (0.30-0.48) <0.001 0.29 (0.22-0.36) <0.001 
     Other   0.58 (0.38-0.89) 0.01 0.42 (0.27-0.64) <0.001 
     
HCV genotype (%)   1 Ref.  Ref.  
     2 0.94 (0.57-1.55) 0.8 0.97 (0.58-1.61) 0.9 
     3 1.83 (1.53-2.18) <0.001 2.03 (1.70-2.42) <0.001 
     4 0.64 (0.49-0.83) 0.001 0.62 (0.47-0.81)  0.001 
     Other/unknown 0.61 (0.42-0.90) 0.01 0.45 (0.30-0.67) <0.001 
     
HCV RNA     ≥800’000 IU/ml Ref.  Ref.  
     <800’000 IU/ml 0.91 (0.78-1.06) 0.2 0.92 (0.78-1.08) 0.3 
     
CD4 cell count, cells/µl  <200 Ref.  Ref.  
     200-349 1.80 (1.30-2.49) <0.001 1.79 (1.29-2.49) 0.001 
     ≥350 1.31 (0.98-1.76) 0.07 1.40 (1.03-1.91) 0.03 
     
Not on ART Ref.  Ref.  
On ART with  detectable HIV RNA  1.12 (0.80-1.57) 0.5 1.15 (0.82-1.63) 0.4 
  with  undetectable HIV RNA  1.06 (0.85-1.33) 0.6 1.00 (0.80-1.26) 1.0 
      
Psychiatric disorder    No Ref.  Ref.  
     Yes 0.65 (0.53-0.81) <0.001 0.67 (0.54-0.83) <0.001 
     
Type of health care provider   University center Ref.  Ref.  
     Affiliated hospital 0.83 (0.64-1.08) 0.2 0.83 (0.64-1.08) 0.2 
     Private physician 1.26 (1.05-1.50) 0.01 1.24 (1.04-1.49) 0.02 
      
Treating time period     2001-2004 Ref.  Ref.  
     2005-2007 0.78 (0.63-0.97) 0.02 0.84 (0.68-1.03) 0.10 
     2008-2010 0.80 (0.64-0.99) 0.04 0.92 (0.73-1.14) 0.4 
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Abbreviations:  ART, antiretroviral therapy; HCV, hepatitis C virus;  IDU, intravenous drug user; MSM, men who have sex with men. 
 
 
 
 
 
 
Supplementary Table 1: Characteristics of HIV-monoinfected, HCV-coinfected untreated and treated participants at date of first visit after 1.1.2001 to 2013. 
 
  
 HCV negative HCV untreated HCV treated P-value* 
  
No. of patients  9291 1471 636  
  
Male gender (%) 6689 (72.0) 971 (66.0) 476 (74.8) <0.001 
  
Median age at last visit   years (IQR) 39 (33-46) 38 (34-43) 39 (35-42) 0.005 
  
HIV transmission group (%)   MSM  4548 (49.0) 138 (9.4) 111 (17.5) <0.001 
     IDU  160 (1.7) 1056 (71.8) 398 (62.6)  
     Heterosexual 4125 (44.4) 244 (16.6) 99 (15.6)  
     Other 458 (4.9) 33 (2.2) 28 (4.4)  
  
CD4 cells/µl     median (IQR) 404 (248-591) 357 (220-559) 408 (257-593) <0.001 
  
Ever on ART (%)    8768 (94.4) 1373 (93.3) 620 (97.5) 0.001 
  
Ever AIDS (%) 2151 (23.2) 432 (29.4) 172 (27.0) <0.001 
  
 
*p-values were calculated by Fisher’s exact tests for categorical and Wilcoxon rank-sum tests for continuous variables.  
Abbreviations:  ART, antiretroviral therapy; HCV, hepatitis C virus;  IDU, intravenous drug user; IQR, interquartile range; MSM, men who have sex with men.  
 
     2011-2013 0.92 (0.73-1.15) 0.5 1.17 (0.91-1.49) 0.3 
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Figure 1:  Patient Flowchart 
 
 
 
 
Abbreviations: HCV, hepatitis C virus; IFN, interferon; SVR, sustained viral response.
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Figure 2:  Kaplan-Meier survival curve of HCV-coinfected untreated, treated, and HIV-monoinfected 
SHCS participants. 
 
 
 
 
 
Abbreviations:  HCV, hepatitis C virus; SVR, sustained viral response. 
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Figure 3: A) Distribution of HCV-coinfected SHCS participants by HCV treatment status, 2001-2013.  
B) Distribution of HCV RNA positive SHCS participants by HCV genotype, 2001-2013 (7.5% unknown 
genotypes are not included). C) Distribution of HCV RNA positive SHCS participants by HIV 
transmission group, 2001-2013. 
 
 
*) HCV RNA was regularly measured after 2001.  
Abbreviations: GT, genotype; OTH, other HIV transmission group; HET, heterosexuals; IDU, 
intravenous drug user; MSM, men who have sex with men; SVR, sustained viral response; tx, 
treatment.  
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